The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Non-Alcoholic Steatohepatitis (NASH) market remains an under-recognized but rapidly growing health concern worldwide. Increasing awareness among both the general public and primary care physicians (PCPs) is crucial for early diagnosis and effective management. Establishing structured referral pathways and patient education initiatives can facilitate timely specialist evaluation and significantly expand the diagnosed patient population.

To address this awareness gap, the NASH Education Program launched a public campaign on June 12, 2018, marking the first "International NASH Day." This initiative aimed to spotlight both non-alcoholic fatty liver disease (NAFLD) and its more advanced form, NASH, which affects over 115 million individuals globally. The campaign sought to educate the public about the risks associated with the disease and the importance of early detection and lifestyle modification.

On June 12, 2019, further efforts were made by NASH 24X7, a digital platform dedicated to raising awareness of the NASH epidemic. As part of its initiatives on International NASH Day, the platform introduced several outreach programs including healthcare provider (HCP) support, patient education campaigns, and media engagement through press and television coverage. These efforts aimed to broaden public understanding and promote proactive liver health management.

In India, the NASH Crusaders initiative under NASH 24X7 collaborated with HCPs to organize multiple educational workshops. These sessions highlighted the importance of liver health and the role of a healthy lifestyle in preventing NAFLD and NASH. Utilizing both digital and print media, the campaign effectively reached a wide audience with critical messages on disease prevention.

Given rising disease prevalence and increased awareness efforts, the European NASH market is projected to grow at a robust compound annual growth rate (CAGR) in the coming years, reflecting the region’s commitment to tackling this public health challenge.

The Europe non-alcoholic steatopatitis market is a significant segment within the broader liver disease treatment landscape, driven by the increasing prevalence of obesity and related metabolic disorders. Here's a breakdown of its segmentation and key players, based on the provided information:

Europe non-alcoholic steatopatitis market Segmentation:

Europe non-alcoholic steatopatitis market Product Type:

• Vitamin E and Pioglitazone
• Ocaliva (Obeticholic Acid)
• Elafibranor
• Selonsertib & Cenicriviroc (expected to be the fastest-growing segment)
• Others (including other investigational and approved therapies)

Europe non-alcoholic steatopatitis market Application:

• Treatment (dominated the market in 2020)
• Diagnosis

Europe non-alcoholic steatopatitis market Sales Channel:

• Hospital Pharmacy
• Online Provider
• Retail Pharmacy (dominated the market in 2020)

Europe non-alcoholic steatopatitis market Country:

• Germany (dominated the market in 2020)
• The UK
• France
• Italy
• Spain
• Rest of Europe

Leading Companies in the Europe non-alcoholic steatopatitis market:

• Cadila Pharmaceutical
• Intercept Pharmaceutical
• Novartis AG
• Galmed Pharmaceutical
• GENFIT
• ONE WAY LIVER SI
• BioPredictive S.A.S
• Siemens Healthineers AG
• Laboratory Corporation of America Holdings

Additional Insights from Search Results: Europe non-alcoholic steatopatitis market

Market Size & Growth:As per our report Europe Non-Alcoholic Steatopatitis Market, the market size is valued at US$ 496.83 Million in 2021, projecting it to reach US$ 6,765.21 Million by 2028. This translates to a CAGR of approximately 45.2% during the forecast period.

Key Drivers: The increasing prevalence of obesity globally is a major growth factor for the NASH treatment market.

Challenges: A major challenge is the lack of appropriate, FDA-approved treatments that can halt or reverse the progression of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma.

Emerging Trends:

• Increased interest in non-invasive diagnostics.
• Development of novel therapies and pharmacological treatments targeting various metabolic, inflammatory, and fibrotic pathways.
• Shift towards combination therapies due to the complex pathogenesis of NASH.
• Rising adoption of telemedicine and e-commerce platforms for healthcare products, driving the online providers segment.

Specific Company Activities:

• Intercept Pharmaceuticals: Their lead product is Ocaliva (obeticholic acid, OCA), though its marketing authorization in Europe was revoked in August 2024. They were acquired by Alfasigma S.p.A.
• Novartis AG: Has a development portfolio in non-viral liver diseases, including NASH, and has entered clinical collaborations to evaluate combination therapies.
• Galmed Pharmaceuticals: Focused on developing Aramchol, with recent patent grants for combination therapy with Resmetirom. They are also exploring broader cardiometabolic indications.
• GENFIT: Has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and a rapidly expanding R&D portfolio in liver diseases. Their product elafibranor (Iqirvo®) has recently received pricing and reimbursement approval in Italy.
• ONE WAY LIVER S.L.: A biotechnology company offering diagnostic products and metabolomics services for liver diseases, including OWLiver for steatosis and NASH diagnosis.
• BioPredictive S.A.S: Offers non-invasive diagnostic tests for liver diseases, including NASH-FibroTest, SteatoTest, and NashTest.
• Siemens Healthineers AG & Laboratory Corporation of America Holdings (Labcorp): These companies are involved in broader healthcare diagnostics and services, which would include solutions and testing relevant to NASH diagnosis and monitoring.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Author’s Bio:

Suryakant Gadekar

Senior Market Research Expert at Business Market Insights